Delving into the Latest Updates on Zhejiang University of Technology with Synapse

Overview

Tags

Neoplasms

Endocrinology and Metabolic Disease

Digestive System Disorders

Small molecule drug

Fusion protein

Monoclonal antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	7
Endocrinology and Metabolic Disease	3
Hemic and Lymphatic Diseases	1
Immune System Diseases	1
Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	7
Monoclonal antibody	1
Fusion protein	1

Top 5 Target	Count

HPV E7	1
ME3(malic enzyme 3)	1
IGF-2(Insulin-like growth factor II)	1
DR5(Tumor necrosis factor receptor superfamily member 10B)	1
RIPK1(Receptor-interacting serine/threonine-protein kinase 1)	1

The electrochemical carbon dioxide reduction reaction (CO₂RR) to high value-added fuels or chemicals driven by the renewable energy is promising to alleviate global warming. However, the selective CO₂ reduction to C₂ products remains challenge. Cu-based catalyst with the specific Cu⁰ and Cu⁺ sites is important to generate C₂ products. This work used nitrogen (N) to tune amounts of Cu⁰ and Cu⁺ sites in Cu₂O catalysts and improve C₂-product conversion. The controllable Cu⁰/Cu⁺ ratio of Cu₂O catalyst from 0.16 to 15.19 was achieved by adjusting the N doping amount using NH₃/Ar plasma treatment. The major theme of this work was clarifying a volcano curve of the ethylene Faraday efficiency as a function of the Cu⁰/Cu⁺ ratio. The optimal Cu⁰/Cu⁺ ratio was determined as 0.43 for selective electroreduction CO₂ to ethylene. X-ray spectroscopy and density functional theory (DFT) calculations were employed to elucidate that the strong interaction between N and Cu increased the binding energy of NCu bond and stabilize Cu⁺, resulting in a 92.3% reduction in the potential energy change for *CO-*CO dimerization. This study is inspiring in designing high performance electrocatalysts for CO₂ conversion.

01 Feb 2025·Tsinghua Science and Technology

BASIL: Binary Anchor-Based Smart Indoor Localization

Author: Zhang, Yufan ; Yang, Zhe ; Chen, Chung Shue ; Zhu, Yi-hua ; Li, Yanjun ; Pan, Yun

01 Feb 2025·Biomaterials

Responsive and traceless assembly of iron nanoparticles and 131I labeled radiopharmaceuticals for ferroptosis enhanced radio-immunotherapy

Article

Author: Chen, Ruifang ; Feng, Kai ; Ruan, Yiling ; Sun, Xiaolian ; Xiong, Hehua ; Yu, Jing ; Zhao, Yaxuan ; Shen, Jingjing ; Zhang, Tao ; Xu, Zhengtao

Ferroptosis is an iron-dependent form of programmed cell death with the potential to reverse traditional cancer therapy resistance. The combination of ferroptosis with chemotherapy, photodynamic therapy and X-ray therapy has demonstrated remarkably improved therapeutic efficiency. Radiopharmaceutical therapy (RPT) is an emerging approach that achieves precise radiation to diseased tissues via radionuclide delivery. However, insufficient accumulation and retention of therapeutic radiopharmaceuticals in tumor region as well as cancer radioresistance impact treatment efficacy. Here, a nanoassembly of renal clearable ultrasmall iron nanoparticles (USINPs) and ¹³¹I-aPD-L1 is prepared via the affinity of fluorophenylboronic acid modified on the USINPs with ¹³¹I-aPD-L1. The 150 nm USINAs(¹³¹I-aPD-L1) nanoassembly is stable in blood circulation, effectively targets to the tumor and disassembles in the presence of ATP in the tumor microenvironment. Both in vitro and in vivo experiments prove that USINPs-induced ferroptosis boosted the tumor radiosensitization to ¹³¹I while ¹³¹I-mediated RPT further enhanced ferroptosis. Meanwhile, the immunogenic cell death caused by RPT and ferroptosis combined with PD-L1 immune checkpoint blockade therapy exhibits a strong antitumor immunity. This study provides a novel way to improve the tumor accumulation of ferroptosis inducer and radiopharmaceuticals, insights into the interaction between RPT and ferroptosis and an effective SPECT-guided ferroptosis-enhanced radio-immunotherapy.

100 Deals associated with Zhejiang University of Technology

Login to view more data

100 Translational Medicine associated with Zhejiang University of Technology

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

4

5

Preclinical

Other

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

FL779	Colorectal Cancer More	Preclinical
SZM-610 ( RIPK1 x RIPK3 )	Inflammation More	Preclinical
FL-776	Colorectal Cancer More	Preclinical
FL-7724	Pancreatic Cancer More	Preclinical
Compound 16b(Sun Pharma) ( ME3 )	Neoplasms More	Preclinical